Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-11-08 | OptimizeRx Corp | Odence-Ford Marion
(General Counsel and CCO) |
M | Common Stock | A | 1785 | $0.00 - $0.00 | $0 |
2024-11-08 | OptimizeRx Corp | Odence-Ford Marion
(General Counsel and CCO) |
F | Common Stock | D | 524 | $6.27 - $6.27 | $3,285 |
2024-11-01 | OptimizeRx Corp | Greco Theresa
(Chief Commercial Officer) |
F | Common Stock | D | 1693 | $5.15 - $5.15 | $8,718 |
2024-10-11 | OptimizeRx Corp | Stelmakh Edward
(CFO/COO) |
M | Common Stock | A | 8222 | $0.00 - $0.00 | $0 |
2024-10-11 | OptimizeRx Corp | Stelmakh Edward
(CFO/COO) |
F | Common Stock | D | 2066 | $6.63 - $6.63 | $13,697 |
2024-10-03 | OptimizeRx Corp | Stelmakh Edward
(CFO/COO) |
M | Common Stock | A | 16622 | $0.00 - $0.00 | $0 |
2024-10-03 | OptimizeRx Corp | Stelmakh Edward
(CFO/COO) |
F | Common Stock | D | 4177 | $7.83 - $7.83 | $32,705 |
2024-10-03 | OptimizeRx Corp | Odence-Ford Marion
(General Counsel and CCO) |
M | Common Stock | A | 6649 | $0.00 - $0.00 | $0 |
2024-10-03 | OptimizeRx Corp | Odence-Ford Marion
(General Counsel and CCO) |
F | Common Stock | D | 1952 | $7.83 - $7.83 | $15,284 |
2024-10-03 | OptimizeRx Corp | Silvestro Stephen L
(Chief Commercial Officer) |
M | Common Stock | A | 6649 | $0.00 - $0.00 | $0 |
2024-10-03 | OptimizeRx Corp | Silvestro Stephen L
(Chief Commercial Officer) |
F | Common Stock | D | 2617 | $7.83 - $7.83 | $20,491 |
2024-10-03 | OptimizeRx Corp | Besch Doug
(Chief Product Officer) |
M | Common Stock | A | 3324 | $0.00 - $0.00 | $0 |
2024-10-03 | OptimizeRx Corp | Besch Doug
(Chief Product Officer) |
F | Common Stock | D | 976 | $7.83 - $7.83 | $7,642 |
2024-04-18 | OptimizeRx Corp | FEBBO WILLIAM J
(CEO) |
M | Common Stock | A | 28895 | $0.00 - $0.00 | $0 |
2024-04-18 | OptimizeRx Corp | FEBBO WILLIAM J
(CEO) |
F | Common Stock | D | 782 | $9.35 - $9.35 | $7,311 |
2024-06-05 | OptimizeRx Corp | Spangler Patrick D
(Director) |
M | Common Stock | A | 10061 | $0.00 - $0.00 | $0 |
2024-06-07 | OptimizeRx Corp | Spangler Patrick D
(Director) |
A | Common Stock | A | 13286 | $0.00 - $0.00 | $0 |
2024-06-05 | OptimizeRx Corp | Vos Ellen O'Connor
(Director) |
M | Common Stock | A | 10061 | $0.00 - $0.00 | $0 |
2024-06-07 | OptimizeRx Corp | Vos Ellen O'Connor
(Director) |
A | Common Stock | A | 13286 | $0.00 - $0.00 | $0 |
2024-06-05 | OptimizeRx Corp | WASSON GREGORY D
(Director) |
M | Common Stock | A | 10061 | $0.00 - $0.00 | $0 |
2024-06-07 | OptimizeRx Corp | WASSON GREGORY D
(Director) |
A | Common Stock | A | 13286 | $0.00 - $0.00 | $0 |
2024-06-05 | OptimizeRx Corp | HALAS GUS D
(Director) |
M | Common Stock | A | 10061 | $0.00 - $0.00 | $0 |
2024-06-07 | OptimizeRx Corp | KLEMA CATHY
(Director) |
A | Common Stock | A | 6643 | $0.00 - $0.00 | $0 |
2024-06-05 | OptimizeRx Corp | Lang James Paul
(Director) |
M | Common Stock | A | 10061 | $0.00 - $0.00 | $0 |
2024-06-07 | OptimizeRx Corp | Lang James Paul
(Director) |
A | Common Stock | A | 13286 | $0.00 - $0.00 | $0 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |